HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (23) Citing Articles via Google Scholar Google Scholar Articles by Büttner, C. Articles by Renz, H. Search for Related Content PubMed PubMed Citation Articles by Büttner, C. Articles by Renz, H.

Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions

¹ Dept of Clinical Immunology and Asthma Outpatient Dept, ² Institute of Laboratory Medicine, Charité, Campus Virchow-Klinikum, Humboldt-Universität, Berlin, and ³ Dept of Clinical Chemistry and Molecular Diagnostics, Philipps-Universität, Marburg, Germany

CORRESPONDENCE: A. Lun, Charité, CVK, Institut für Laboratoriumsmedizin und Pathobiochemie, Augustenburger Platz 1, 13353, Berlin, Germany. Fax: 49 30450569900. E-mail: andreas.lun@charite.de

Keywords: asthma, eosinophils, interleukin-5, lymphocytes, treatment

Received: April 3, 2002
Accepted January 24, 2003

This study was supported in part by a grant from SmithKline Beecham, Harlow, UK.

Influx of eosinophils in airway mucosa and airway lumen is a hallmark of bronchial asthma. In-vitro data and animal studies indicate that the T-helper (Th) type-2 cell cytokine, interleukin (IL)-5, plays an important role in eosinophil maturation, differentiation, recruitment, and survival. The objective of this study was to determine whether intravenous treatment with monoclonal anti-IL-5 would affect the number of peripheral blood eosinophils, their activation status, T-cell activation or the pattern of Th1 and Th2 cytokine production.

Over a period of 6 months, 19 asthmatics were investigated in a double-blind, placebo-controlled, multicentre study with mepolizumab (SB 240563) anti-IL-5 antibody administered three times. Before each infusion and 12 weeks after the last infusion, peripheral blood leukocytes were examined, qualitative and quantitative distribution of eosinophils and lymphocyte subpopulations, frequencies of IL-2, -3, -4, -5, -10, -13, interferon--producing CD4 T-cells and serum eosinophil cationic protein (ECP) levels were determined.

Treatment with mepolizumab resulted in a marked, rapid and sustained decrease of eosinophil numbers (median values from 300 to 45 per µL) paralleled by decreased levels of serum ECP (median values from 15 to 5 µg·L^–1). Distribution of T-cell subsets and T-cell cytokine production were not altered during antibody treatment.

In conclusion, administration of mepolizumab to asthmatic patients markedly reduces peripheral blood eosinophils without altering the distribution and activation status of lymphocytes.

This article has been cited by other articles:

				M. E. Rothenberg, A. D. Klion, F. E. Roufosse, J. E. Kahn, P. F. Weller, H.-U. Simon, L. B. Schwartz, L. J. Rosenwasser, J. Ring, E. F. Griffin, et al. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab N. Engl. J. Med., March 20, 2008; 358(12): 1215 - 1228. [Abstract] [Full Text] [PDF]

				M. M. Gorska, O. Cen, Q. Liang, S. J. Stafford, and R. Alam Differential Regulation of Interleukin 5-stimulated Signaling Pathways by Dynamin J. Biol. Chem., May 19, 2006; 281(20): 14429 - 14439. [Abstract] [Full Text] [PDF]

				S. T. Holgate, J. Holloway, S. Wilson, F. Bucchieri, S. Puddicombe, and D. E. Davies Epithelial-Mesenchymal Communication in the Pathogenesis of Chronic Asthma Proceedings of the ATS, April 1, 2004; 1(2): 93 - 98. [Abstract] [Full Text] [PDF]